COMPLICATIONS IN RHEUMATOID ARTHRITIS PATIENTS  FOLLOWING KNEE JOINT REPLACEMENT: FINDINGS FROM A 26- WEEK PROSPECTIVE REAL-WORLD COHORT STUDY

dc.contributor.author	Maruf Anorboev., Khalmurad Akhmedov., Ilkhom Khujanazarov
dc.date.accessioned	2026-06-12T09:12:56Z
dc.date.available	2026-06-12T09:12:56Z
dc.date.issued	2025-10-18
dc.identifier.uri	http://repo.tma.uz/xmlui/handle/1/4355
dc.description.abstract	Background: Reactive Arthritis (ReA) is an immune-mediated form of spondyloarthritis, often triggered by genitourinary or gastrointestinal infections. Current therapeutic strategies rely mainly on NSAIDs and cs-DMARDs, with biologics reserved for refractory disease. However, limited progress has been made in exploring novel targeted agents. Iguratimod 25 mg, an oral immunomodulatory drug approved for rheumatoid arthritis in Asia, has demonstrated anti-inflammatory and cytokine-suppressive properties, but evidence in ReA is scarce. Objectives: To evaluate the clinical efficacy and cytokine-modulating effects of Iguratimod 25 mg in patients with Reactive Arthritis compared to conventional and biologic therapy.	en_US
dc.language.iso	en_US	en_US
dc.publisher	O'zbekiston, Termiz “FARMAKOLOGIYA, FARMATSEVTIKA VA XALQ TABOBATI: DOLZARB MUAMMOLAR VA INNOVATSIYALAR” MAVZUSIDAGI XALQARO ILMIY-AMALIY KONFERENSIYASI MATERIALLARI TO'PLAMI	en_US
dc.title	COMPLICATIONS IN RHEUMATOID ARTHRITIS PATIENTS FOLLOWING KNEE JOINT REPLACEMENT: FINDINGS FROM A 26- WEEK PROSPECTIVE REAL-WORLD COHORT STUDY	en_US
dc.type	Thesis	en_US